Literature DB >> 30381484

Mutations in Influenza A Virus Neuraminidase and Hemagglutinin Confer Resistance against a Broadly Neutralizing Hemagglutinin Stem Antibody.

Kristina L Prachanronarong1, Aneth S Canale1, Ping Liu2, Mohan Somasundaran1, Shurong Hou1, Yu-Ping Poh3, Thomas Han4, Quan Zhu4, Nicholas Renzette5, Konstantin B Zeldovich3, Timothy F Kowalik5, Nese Kurt-Yilmaz1, Jeffrey D Jensen6, Daniel N A Bolon1, Wayne A Marasco4, Robert W Finberg2, Celia A Schiffer1, Jennifer P Wang7.   

Abstract

Influenza A virus (IAV), a major cause of human morbidity and mortality, continuously evolves in response to selective pressures. Stem-directed, broadly neutralizing antibodies (sBnAbs) targeting the influenza virus hemagglutinin (HA) are a promising therapeutic strategy, but neutralization escape mutants can develop. We used an integrated approach combining viral passaging, deep sequencing, and protein structural analyses to define escape mutations and mechanisms of neutralization escape in vitro for the F10 sBnAb. IAV was propagated with escalating concentrations of F10 over serial passages in cultured cells to select for escape mutations. Viral sequence analysis revealed three mutations in HA and one in neuraminidase (NA). Introduction of these specific mutations into IAV through reverse genetics confirmed their roles in resistance to F10. Structural analyses revealed that the selected HA mutations (S123G, N460S, and N203V) are away from the F10 epitope but may indirectly impact influenza virus receptor binding, endosomal fusion, or budding. The NA mutation E329K, which was previously identified to be associated with antibody escape, affects the active site of NA, highlighting the importance of the balance between HA and NA function for viral survival. Thus, whole-genome population sequencing enables the identification of viral resistance mutations responding to antibody-induced selective pressure.IMPORTANCE Influenza A virus is a public health threat for which currently available vaccines are not always effective. Broadly neutralizing antibodies that bind to the highly conserved stem region of the influenza virus hemagglutinin (HA) can neutralize many influenza virus strains. To understand how influenza virus can become resistant or escape such antibodies, we propagated influenza A virus in vitro with escalating concentrations of antibody and analyzed viral populations by whole-genome sequencing. We identified HA mutations near and distal to the antibody binding epitope that conferred resistance to antibody neutralization. Additionally, we identified a neuraminidase (NA) mutation that allowed the virus to grow in the presence of high concentrations of the antibody. Virus carrying dual mutations in HA and NA also grew under high antibody concentrations. We show that NA mutations mediate the escape of neutralization by antibodies against HA, highlighting the importance of a balance between HA and NA for optimal virus function.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  broadly neutralizing antibody; hemagglutinin; influenza virus; mutants; neuraminidase; resistance

Mesh:

Substances:

Year:  2019        PMID: 30381484      PMCID: PMC6321927          DOI: 10.1128/JVI.01639-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Amino acid changes in hemagglutinin contribute to the replication of oseltamivir-resistant H1N1 influenza viruses.

Authors:  Teridah Ernala Ginting; Kyoko Shinya; Yukihiro Kyan; Akiko Makino; Naomi Matsumoto; Satoko Kaneda; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

2.  Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 northern hemisphere season.

Authors:  Ian G Barr; John McCauley; Nancy Cox; Rod Daniels; Othmar G Engelhardt; Keiji Fukuda; Gary Grohmann; Alan Hay; Anne Kelso; Alexander Klimov; Takato Odagiri; Derek Smith; Colin Russell; Masato Tashiro; Richard Webby; John Wood; Zhiping Ye; Wenqing Zhang
Journal:  Vaccine       Date:  2009-12-09       Impact factor: 3.641

3.  Structural characterization of an early fusion intermediate of influenza virus hemagglutinin.

Authors:  Rui Xu; Ian A Wilson
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

4.  WFABC: a Wright-Fisher ABC-based approach for inferring effective population sizes and selection coefficients from time-sampled data.

Authors:  Matthieu Foll; Hyunjin Shim; Jeffrey D Jensen
Journal:  Mol Ecol Resour       Date:  2014-06-11       Impact factor: 7.090

Review 5.  Antibody recognition of the influenza virus neuraminidase.

Authors:  G M Air; W G Laver; R G Webster; M C Els; M Luo
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1989

6.  Dengue Virus NS2B/NS3 Protease Inhibitors Exploiting the Prime Side.

Authors:  Kuan-Hung Lin; Akbar Ali; Linah Rusere; Djade I Soumana; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

7.  Structure of a classical broadly neutralizing stem antibody in complex with a pandemic H2 influenza virus hemagglutinin.

Authors:  Cyrille Dreyfus; Damian C Ekiert; Ian A Wilson
Journal:  J Virol       Date:  2013-04-03       Impact factor: 5.103

Review 8.  Receptor binding and pH stability - how influenza A virus hemagglutinin affects host-specific virus infection.

Authors:  Caroline M Mair; Kai Ludwig; Andreas Herrmann; Christian Sieben
Journal:  Biochim Biophys Acta       Date:  2013-10-24

9.  Analysis of residues near the fusion peptide in the influenza hemagglutinin structure for roles in triggering membrane fusion.

Authors:  Sudha Thoennes; Zhu-Nan Li; Byeong-Jae Lee; William A Langley; John J Skehel; Rupert J Russell; David A Steinhauer
Journal:  Virology       Date:  2007-10-23       Impact factor: 3.616

10.  Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses.

Authors:  Susu Duan; Elena A Govorkova; Justin Bahl; Hassan Zaraket; Tatiana Baranovich; Patrick Seiler; Kristi Prevost; Robert G Webster; Richard J Webby
Journal:  Nat Commun       Date:  2014-10-09       Impact factor: 14.919

View more
  15 in total

1.  Picomolar to Micromolar: Elucidating the Role of Distal Mutations in HIV-1 Protease in Conferring Drug Resistance.

Authors:  Mina Henes; Gordon J Lockbaum; Klajdi Kosovrasti; Florian Leidner; Gily S Nachum; Ellen A Nalivaika; Sook-Kyung Lee; Ean Spielvogel; Shuntai Zhou; Ronald Swanstrom; Daniel N A Bolon; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  ACS Chem Biol       Date:  2019-08-13       Impact factor: 5.100

Review 2.  VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design.

Authors:  Fang Chen; Netanel Tzarum; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2019-03-16       Impact factor: 7.090

Review 3.  Influenza Virus Entry inhibitors.

Authors:  Jie Yang; Shuwen Liu
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

4.  Interactions between Influenza A Virus Nucleoprotein and Gene Segment Untranslated Regions Facilitate Selective Modulation of Viral Gene Expression.

Authors:  Meghan Diefenbacher; Timothy J C Tan; David L V Bauer; Beth M Stadtmueller; Nicholas C Wu; Christopher B Brooke
Journal:  J Virol       Date:  2022-04-25       Impact factor: 6.549

5.  Matrix Protein 2 Extracellular Domain-Specific Monoclonal Antibodies Are an Effective and Potentially Universal Treatment for Influenza A.

Authors:  Lynn Bimler; Sydney L Ronzulli; Amber Y Song; Scott K Johnson; Cheryl A Jones; Teha Kim; Duy T Le; S Mark Tompkins; Silke Paust
Journal:  J Virol       Date:  2020-12-02       Impact factor: 6.549

6.  Generation of a protective murine monoclonal antibody against the stem of influenza hemagglutinins from group 1 viruses and identification of resistance mutations against it.

Authors:  Wei Wang; Russell Vassell; Hyo Sook Song; Qiong Chen; Paul W Keller; Swati Verma; Esmeralda Alvarado-Facundo; Hongquan Wan; Falko Schmeisser; Clement A Meseda; Jerry P Weir; Carol D Weiss
Journal:  PLoS One       Date:  2019-09-12       Impact factor: 3.240

Review 7.  Influenza and antiviral resistance: an overview.

Authors:  Temi Lampejo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-02-13       Impact factor: 3.267

8.  High-throughput human primary cell-based airway model for evaluating influenza, coronavirus, or other respiratory viruses in vitro.

Authors:  A L Gard; R J Luu; C R Miller; R Maloney; B P Cain; E E Marr; D M Burns; R Gaibler; T J Mulhern; C A Wong; J Alladina; J R Coppeta; P Liu; J P Wang; H Azizgolshani; R Fennell Fezzie; J L Balestrini; B C Isenberg; B D Medoff; R W Finberg; J T Borenstein
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

9.  Phylogenetic analysis and clinical characteristics of the co-occurring mutations in HA and NA genes of influenza A(H1N1)pdm09 viruses during 2015-2017 in Beijing, China.

Authors:  Yafen Liu; Yue Wang; Baiyi Liu; Xu Cong; Ying Ji; Xiaolin Guo; Yan Gao
Journal:  Virol J       Date:  2020-11-19       Impact factor: 4.099

10.  Structure-Based Modification of an Anti-neuraminidase Human Antibody Restores Protection Efficacy against the Drifted Influenza Virus.

Authors:  Haihai Jiang; Weiyu Peng; Jianxun Qi; Yan Chai; Hao Song; Yuhai Bi; Pramila Rijal; Haiyuan Wang; Babayemi O Oladejo; Jinhua Liu; Yi Shi; George F Gao; Alain R Townsend; Yan Wu
Journal:  mBio       Date:  2020-10-06       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.